echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Diabetes, Obesity and Metabolism: Data from 500,000 people suggest that cognitive impairment may begin in prediabetes

    Diabetes, Obesity and Metabolism: Data from 500,000 people suggest that cognitive impairment may begin in prediabetes

    • Last Update: 2021-02-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    At present, the scientific community agrees that people with diabetes have a wide range of cognitive impairments, such as memory loss, distraction, and decreased execution.
    sea mass is closely related to cognitive function.
    is the center of learning, memory, and directional nerves.
    found that at high blood sugar, the production of reactive oxygen drinking free agents, glucose toxicity to neurons led to damage to the sea horse.
    although there is much evidence that diabetes can cause neurodegenerative lesions, the effects of blood sugar on the brain remain unclear throughout the blood sugar spectrum.
    especially in low hyperglycemia states.
    a recent study published in the journal Diabtes, Obesity and Metabolism found that people with higher-than-normal blood sugar levels were 42 percent more likely to have cognitive decline and an average 54 percent higher risk of developing vascular dementia.
    the study, researchers asked 500,000 participants aged 40-69 from the UK Biobank database how different blood sugar levels or blood sugar states affect cognitive function.
    the participants were tested with HbA1c, which determined average blood sugar levels over the past 2 to 3 months, and were divided into five groups based on the results: known diabetes, undiagnosed diabetes, and prediabetes (HbA1c in 4 2 to 48 mmol/mol), normal blood sugar (HbA1c at 35 to 42 mmol/mol) and hypoglycemia (HbA1c at .lt;35 mmol/mol).
    results showed that participants were repeatedly assessed for visual memory data to determine whether they had cognitive decline.
    the absolute rate of cognitive decline was low, pre-diabetics and diabetics were similarly likely to have cognitive decline, at 42 percent and 39 percent, respectively.
    the relationship between blood sugar and cognitive function in the diagnosis of dementia, the researchers found that pre-diabetes and vascular dementia are more likely.
    , diabetics are three times more likely to develop vascular dementia than normal blood sugar levels, and at higher risk of Alzheimer's disease.
    , undiagnosed diabetes, prediabetes, and known diabetics have higher and smaller sea mass (WMH) in the brain whiteness.
    those taking antihypypants may have more WMH and smaller sea mass.
    , both pre-diabetes and known diabetes were significantly associated with vascular dementia, cognitive decline, AD risk, and decreased sea mass volume.
    pre-diabetes can reduce the risk of type 2 diabetes by eating a healthy diet, eating a balanced diet, exercise more and maintaining a healthy weight.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.